December 6, 2023

Mathematical Model Provides Further Insight on Spatially Fractionated Radiotherapy

Study offers a foundation for additional research to examine radiation and immune response

23-CNR-4198921-CQD-Hero-650×450 Dr Cho 2

A recent research effort—led by a team of Cleveland Clinic experts—explored radio-immune response modeling for cancer patients, shedding light on the effect radiation has on the immune response. These findings, which were recently published in the journal Physics in Medicine & Biology, lay the groundwork for future clinical trials.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“There has been a renewed interest in spatially fractionated radiotherapy, historically known as GRID therapy,” says study author Jacob G. Scott, MD, DPhil, Department of Translational Hematology and Oncology Research at Cleveland Clinic. “Unlike the standard approach, spatially fractionated radiotherapy delivers highly heterogeneous dose distributions and has proven beneficial for large tumors that are typically difficult to treat with conventional radiotherapy.”

While previous studies have demonstrated its effectiveness, less is known about the “why” behind this approach, according to Dr. Scott. To address this knowledge gap, the Cleveland Clinic team, including Young-Bin Cho, PhD, Department of Radiation Oncology, developed a mathematical model that allows for deeper investigation of the immune process and its role in radiotherapy.

Study findings and key takeaways

In this study, Dr. Cho and colleagues used existing models to create an ordinary differential equation model of tumor growth with radiation and the immune system. This new tumor model has four compartments: viable tumor cells, T-cell lymphocytes, immune triggering cells and doomed cells.

The researchers identified and analyzed two distinctive modes of tumor status—immune limited and immune escape. “Tumors in the immune limited mode can grow only up to a finite size,” explains Dr. Cho.

Advertisement

“The dynamics of the tumor growth in the immune escape mode is much more complex than the tumors in the immune limited mode, especially when the status of the tumor is close to the bifurcation condition,” Cho and his colleagues reported in their recent paper. “Radiation can kill tumor cells not only by radiation damage but also by boosting immune reaction.”

Using this model, the researchers showed that spatially fractionated radiotherapy can have a significant impact on tumor cell killing when compared to the more traditional homogeneous dose distribution approach.

“Spatially fractionated radiotherapy can not only enhance but also moderate the cell killing, depending on the immune response triggered by many factors, such as dose prescription parameters, tumor volume at the time of treatment and tumor characteristics,” notes Dr. Cho and team, who demonstrated this by applying their model to prior data on 67NR murine tumors as well as a sarcoma patient.

Implications and next steps

“Continuing to improve our understanding of the role and response of the immune system both during and following radiotherapy is crucial, says Dr. Scott. “Our model has the potential to help determine when novel methods, such as spatially fractionated radiotherapy, are warranted. Additionally, it could support efforts to amplify the synergistic effect of radiation and immunotherapies.”

Advertisement

This begins by delving deeper into the hypotheses produced by this study in regard to how radiation and the immune system interact. Dr. Cho and his colleagues plan to conduct laboratory studies to further explore this area of investigation. Another avenue of research involves taking a closer look at existing clinical data to validate the effectiveness of their mathematical model. Through these efforts, the research team hopes to take this model and move toward a clinical study.

“The interaction between radiation therapy and the immune system is a complex dynamic process,” says Dr. Cho. “Therefore, understanding the background mechanism is important to design successful clinical trials. Many studies have looked at static aspects of the immune response and do not provide a complete picture of the mechanism.“

“Our model, hopefully, can help us better understand the dynamic mechanism of the immune response, so that we and others can design more effective clinical trials in the future,” he concludes, while emphasizing that their model has a variety of implications not only for the use of spatially fractionated radiotherapy, but also more standard radiation approaches. “We are very excited to continue our work with this model and to better understand its potential impact on future research and clinical care.”

Related Articles

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

23-CNR-4318382-CQD-Hero-650×450 Dr Hill
December 19, 2023
Active Surveillance may be a Feasible Option for a Subset of Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Large cohort study finds no reduction in survival for patients managed with active surveillance compared to treated patients

Dr. Caimi
December 15, 2023
CAR-T Cell Therapy Effective in Refractory Double-Hit/Triple-Hit Lymphoma

Two thirds of patients responded to CAR T-cell therapy

23-CNR-4344308-CQD-Hero-650×450 Ornstein
December 14, 2023
Belzutifan Shows Improvement in Progression-Free Survival for Patients with Refractory Clear-Cell Kidney Cancer

Belzutifan superior to everolimus in phase 3 clinical trial

Relapsed refractory multiple myeloma treatment
December 12, 2023
Teclistamab Appears Safe and Effective in Real-World Patients with Relapsed/Refractory Multiple Myeloma

Despite sicker patients, response rates of teclistamab in a real-world study were similar to those from a pivotal clinical trial

Ad